Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John L Sever

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
American Journal of Obstetrics and Gynecology|January 19, 2008
Group B Streptococcus and pregnancy: a reviewJohn W Larsen, John L Sever
The Journal of Infectious Diseases|August 26, 2017
Rotary's PolioPlus Program: Lessons Learned, Transition Planning, and LegacyJohn L Sever, Michael McGovern, Robert Scott, et al.
Therapeutic Drug Monitoring|July 2, 2004
Therapeutic drug monitoring for patients with HIV infection: Children's National Medical Center, Washington DC experienceSteven J Soldin, Natella Y Rakhmanina, Hans M L Spiegel, et al.
Pharmacoepidemiology and Drug Safety|June 8, 2002
Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)John L Sever, Alan I Brenner, Arnold D Gale, et al.
The Journal of Infectious Diseases|August 26, 2017
Polio Endgame: Lessons Learned From the Immunization Systems Management GroupSimona Zipursky, Jos Vandelaer, Alan Brooks, et al.
Pharmacoepidemiology and Drug Safety|September 24, 2004
Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)John L Sever, Alan I Brenner, Arnold D Gale, et al.
Therapeutic Drug Monitoring|February 17, 2007
Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infectionNatella Y Rakhmanina, Edmund V Capparelli, John N van den Anker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 18, 2003
Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthraxBruce C Tierney, Stacey W Martin, Laura H Franzke, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
American Journal of Obstetrics and Gynecology|January 19, 2008
Group B Streptococcus and pregnancy: a reviewJohn W Larsen, John L Sever
The Journal of Infectious Diseases|August 26, 2017
Rotary's PolioPlus Program: Lessons Learned, Transition Planning, and LegacyJohn L Sever, Michael McGovern, Robert Scott, et al.
Therapeutic Drug Monitoring|July 2, 2004
Therapeutic drug monitoring for patients with HIV infection: Children's National Medical Center, Washington DC experienceSteven J Soldin, Natella Y Rakhmanina, Hans M L Spiegel, et al.
Pharmacoepidemiology and Drug Safety|June 8, 2002
Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)John L Sever, Alan I Brenner, Arnold D Gale, et al.
The Journal of Infectious Diseases|August 26, 2017
Polio Endgame: Lessons Learned From the Immunization Systems Management GroupSimona Zipursky, Jos Vandelaer, Alan Brooks, et al.
Pharmacoepidemiology and Drug Safety|September 24, 2004
Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)John L Sever, Alan I Brenner, Arnold D Gale, et al.
Therapeutic Drug Monitoring|February 17, 2007
Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infectionNatella Y Rakhmanina, Edmund V Capparelli, John N van den Anker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 18, 2003
Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthraxBruce C Tierney, Stacey W Martin, Laura H Franzke, et al.
Pageof 1